![]() ![]() “The quality of the investor syndicate and magnitude of the round reflects the value we have built in our discovery capabilities and the progress we have made in our preclinical programs since our Series B financing just a year ago.”Ītreca’s aim is ambitious and should give hope to patients suffering from solid tumors, including breast, lung, and colon cancers. “Our oversubscribed Series C financing provides further validation of Atreca’s ability to discover and develop high-potential therapeutic candidates via its unique approach,” said Brian Atwood, Chairman of the Board of Directors of Atreca. Money will help Atreca advance its lead candidate into clinical trials Orwin, President and Chief Executive Officer of Atreca. “This funding enables us to broaden and accelerate our discovery and pipeline generation efforts and to move our first candidate into clinical development,” said John A. The exclusive placement agent in this financement was Cowen. President and CEO John Orwin said the result of this oversubscribed series C round was good and should give the company runway through 2020. They were joined by various new investors: Aisling Capital, Boxer Capital of the Tavistock Group, EcoR1 Capital, Redmile Group, Samsara BioCapital, and Tekla Capital Management-run funds. Other existing investors, including Wellington Management Company LLC, and Cormorant Asset Management, based in Boston, took part in this latest funding round. This Series C round was led by a previous Atreca investor who remained undisclosed, being presented only as a large U.S.-based, healthcare-focused fund. ![]() Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced the closing of an oversubscribed $125 million financing on September 12th. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |